Naslov
MOPP/ABV hybrid treatment for advanced Hodgkin's Disease (HD) and Anaplastic Large Cell Lymphoma (ALCL) : Single institution experience

Autori
Ostojić, Slobodanka ; Radić-Krišto, Delfa ; Planinc-Peraica, Ana ; Minigo, Hrvoje ; Rudan, Igor ; Jakšić, Ozren ; Kardum-Skelin, Ika ; Jakšić, Branimir

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, ostalo

Izvornik
Abstract Book / Gahrton, G. - : ISH, 1997, 106-106

Skup
Meeting of the International Society of Haematology

Mjesto i datum
Stockholm, Švedska, 30.08.1997. - 04.09.1997

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
Hodgkin lymphoma; therapy

Sažetak
MOPP/ABV hybrid chemotherapy was introduced in for front-line treatment of advanced Hodkgin’s disease (HD) to deliver the dose intensive treatment with acceptable tolerance. We report the results of a study designed to evaluate the efficacy, response predictors, toxicity predictors and overall tolerance of this combination chemotherapy in single institution. Sixty-one consecutive, newly diagnosed patients (51 with advanced HD and 10 with ALCL, 41% males, with median age of 32 years, stage I-II 47%, III-IV 53% were) treated in the period 1990-1996 with 6 cycles of MOPP/ABV hybrid chemotherapy. Median trial time was more then 25 months. Response was classified 1 month after completion of 6 cycles. Complete response was obtained in 51 patients (84%), partial response in 9 (15%) and non response in 1 (2%) of patients. Age, sex, stage, histology, presence of symptoms, ESR, E, Hb, Hct, Tr, Rtc, Fe, UIBC, Cu, L, Bil, SGOT, SGPT, AP, LDH, BM infiltration. ..failed to predict response. Only absolute lymphocyte count was associated with response at the significant level (p=0.0031), stage was borderline significant (p=0.054). Projected DFS at 8 years is 75%, overall survival at 8 years is 60%. Chemotherapy was delivered to the patients in more then 98% of theoretical dose intensity. No toxicity was observed in 49, grade I-II toxicity in 10 and III-IV in 2 patients. Only platelet count and bilirubin at diagnosis were found to be associated with dose reduction at the significant level. Overall tolerance was very good. Results are comparable to other series with HD. This treatment was also efficient in ALCL patients. In conclusion, MOPP/ABV hybrid chemotherapy is well tolerated and effective treatment for remission induction in advanced HD and ALCL.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA